A detailed history of Summit Global Investments transactions in Harmony Biosciences Holdings, Inc. stock. As of the latest transaction made, Summit Global Investments holds 19,263 shares of HRMY stock, worth $618,920. This represents 0.05% of its overall portfolio holdings.

Number of Shares
19,263
Previous 20,164 4.47%
Holding current value
$618,920
Previous $608,000 26.81%
% of portfolio
0.05%
Previous 0.04%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 31, 2024

SELL
$30.0 - $39.95 $27,030 - $35,994
-901 Reduced 4.47%
19,263 $771,000
Q2 2024

Jul 22, 2024

BUY
$28.81 - $33.01 $23,249 - $26,639
807 Added 4.17%
20,164 $608,000
Q1 2024

Apr 29, 2024

BUY
$29.93 - $35.06 $95,297 - $111,631
3,184 Added 19.69%
19,357 $650,000
Q4 2023

Feb 06, 2024

BUY
$19.2 - $33.78 $310,521 - $546,323
16,173 New
16,173 $522,000
Q2 2023

Jul 18, 2023

BUY
$30.5 - $37.4 $299,723 - $367,529
9,827 New
9,827 $346,000

Others Institutions Holding HRMY

About Harmony Biosciences Holdings, Inc.


  • Ticker HRMY
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 59,161,400
  • Market Cap $1.9B
  • Description
  • Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, develops and commercializes therapies for patients with rare neurological disorders in the United States. Its product, WAKIX is a medication for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. The company was formerly known as Harmony ...
More about HRMY
Track This Portfolio

Track Summit Global Investments Portfolio

Follow Summit Global Investments and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Summit Global Investments, based on Form 13F filings with the SEC.

News

Stay updated on Summit Global Investments with notifications on news.